Key Points
- Director Keith Meister sold 68,108 Illumina shares for approximately $14.5 million at an average price of $213.28, reducing his direct ownership by 6.59% to 965,802 shares.
- Illumina reported quarterly EPS of $1.31, exceeding the $1.23 consensus estimate, while revenue rose 9.4% year over year to $1.16 billion. The company maintained fiscal 2026 EPS guidance of $5.30–$5.40.
- Analyst sentiment remains mixed: nine analysts rate the stock a Buy, seven a Hold, and two a Sell, resulting in a consensus Hold rating and a $191.31 price target.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) Director Keith Meister sold 68,108 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $213.28, for a total transaction of $14,526,074.24. Following the completion of the sale, the director directly owned 965,802 shares in the company, valued at $205,986,250.56. This trade represents a 6.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Illumina Price Performance
NASDAQ:ILMN opened at $218.22 on Friday. The firm's fifty day moving average is $198.42 and its two-hundred day moving average is $159.03. The firm has a market cap of $32.95 billion, a price-to-earnings ratio of 40.71, a PEG ratio of 3.14 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a one year low of $88.00 and a one year high of $231.81.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the business posted $1.19 EPS. The company's revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts expect that Illumina, Inc. will post 5.36 EPS for the current year.
Wall Street Analyst Weigh In
Several research firms have commented on ILMN. Deutsche Bank Aktiengesellschaft lowered Illumina to a "hold" rating in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Illumina from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Daiwa Securities Group upgraded shares of Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 target price for the company in a research note on Thursday, May 14th. Royal Bank Of Canada increased their price target on shares of Illumina from $170.00 to $230.00 and gave the stock an "outperform" rating in a report on Friday, July 31st. Finally, Evercore restated an "outperform" rating on shares of Illumina in a research report on Monday, July 6th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $191.31.
Check Out Our Latest Stock Analysis on Illumina
More Illumina News
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
- Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
- Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
- Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
- Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
Hedge Funds Weigh In On Illumina
Hedge funds have recently bought and sold shares of the business. Fiduciary Financial Advisors acquired a new stake in Illumina in the second quarter valued at approximately $26,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina during the 2nd quarter worth approximately $32,000. Rakuten Securities Inc. purchased a new position in shares of Illumina during the 2nd quarter valued at approximately $33,000. Elyxium Wealth LLC acquired a new stake in Illumina in the 4th quarter valued at $25,000. Finally, Elevation Wealth Partners LLC grew its stake in Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company's stock valued at $43,000 after acquiring an additional 84 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.
About Illumina
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
